Invesco Biotechnology & Genome ETF
PBE
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 11 Greenway Plaza, Suite 1000 Houston TX United States of America 77046
- IPO Date
- Jun 23, 2005
- CIK
- 0001209466
- Website
- invesco.com
- Similar Companies
- Business
- Invesco Biotechnology & Genome ETF (PBE) is an exchange-traded fund that seeks to track the investment results of the Dynamic Biotechnology & Genome Intellidex Index, which consists of U.S.-listed biotechnology stocks selected principally on the basis of their potential for investment value from fundamental analysis; the fund invests at least 90% of its total assets in common stocks, American depositary receipts, and global depositary receipts that comprise the underlying index. PBE offers investors targeted exposure to the biotechnology and genome sectors through a portfolio of approximately 30 holdings, including leading companies in gene editing, drug discovery, diagnostics, and therapeutic development such as CRISPR Therapeutics, Beam Therapeutics, Twist Bioscience, and Exelixis; it employs a rules-based methodology emphasizing growth potential, valuation metrics, and momentum factors while maintaining sector purity in biotechnology innovation. The ETF operates globally with a focus on U.S.-domiciled equities but includes international exposure via depositary receipts; it was launched in 2005 and is managed by Invesco Distributors, Inc., headquartered in Atlanta, Georgia. Recent developments include Invesco's ongoing enhancements to its suite of thematic ETFs amid rising investor interest in biotechnology driven by advancements in genomics and personalized medicine, with PBE experiencing portfolio rebalancing in late 2024 to incorporate emerging leaders in mRNA technologies and AI-driven drug design following the sector's recovery from pandemic-era volatility. In 2025, Invesco announced strategic alliances with genome sequencing firms to bolster index methodology data integration, alongside a minor assets under management increase tied to new product launches like complementary precision medicine ETFs; no major acquisitions or name changes have occurred, but the fund benefited from a tactical shift toward small- and mid-cap biotech innovators amid regulatory tailwinds from FDA approvals in gene therapies. PBE serves institutional and retail investors targeting high-growth healthcare subsectors, with geographic operations centered in North America and principal trading on the NYSE Arca exchange.